Theravance Bioph Stock Price, News & Analysis

Theravance Biopharma (NASDAQ: TBPH) has scheduled its third quarter 2024 financial results announcement and business update for November 12, 2024, after market close. The company will host a conference call and simultaneous webcast at 5:00 pm EST on the same day. Interested participants can pre-register for the telephone conference, while those preferring to listen via the internet can access the webcast through Theravance's website. A replay will be available online for 30 days until December 12, 2024.

Theravance Biopharma announced the publication of a sub-study of pivotal Phase 3 trials for YUPELRI (revefenacin), the first FDA-approved once-daily nebulized long-acting muscarinic antagonist (LAMA) for COPD. The study, published in the International Journal of Chronic Obstructive Pulmonary Disease, evaluated the area under the curve (AUC) lung function effects in moderate-to-very-severe COPD patients.

Key findings include:

• Revefenacin improved bronchodilation versus placebo in COPD patients
• Rapid onset of bronchodilation was observed, with a mean FEV1 difference of 145 mL at 15 minutes
• Day 84 bronchodilation improvements were sustained over 24 hours vs. placebo
• FEV1 AUC measurements provide additional information on the magnitude and consistency of bronchodilation throughout the dosing interval

The study reinforces that YUPELRI provides consistent and durable improvements in lung function over a full 24-hour period.

Theravance Biopharma (NASDAQ: TBPH) has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference in New York City. The company will engage in a Fireside Chat on Tuesday, September 10 at 10:00 am ET (7:00 am PT/3:00 pm IST). Additionally, Theravance Biopharma will host in-person meetings with the investment community during the conference.

Investors and interested parties can access a webcast of the event through the company's website, Theravance.com, under the Investors section, Events and Presentations. The webcast replay will be available on the company's website for 30 days following the event, providing an opportunity for those unable to attend live to catch up on the discussion.

Theravance Biopharma reported Q2 2024 financial results and provided a business update. YUPELRI net sales decreased 1% to $54.5 million, while Viatris collaboration revenue increased 4% to $14.3 million. The company updated its timeline for the CYPRESS study, now expecting the last patient enrollment in mid-2025. TRELEGY net sales reached $1.065 billion, increasing the likelihood of achieving up to $50 million in milestones in 2024. Theravance ended Q2 with a cash balance of $96.1 million. The company is exploring opportunities to unlock value from its Irish tax assets and has updated its 2024 financial guidance.

Theravance Biopharma (NASDAQ: TBPH) has announced its participation in the upcoming BTIG Virtual Biotechnology Conference. The company will engage in a fireside chat on Tuesday, August 6 at 12:00 pm ET (9:00 am PT/5:00 pm IST). In addition to the chat, Theravance Biopharma's senior management team will be available for one-on-one meetings with investors during the conference.

Interested parties can access the webcast or schedule meetings with the management team by contacting their BTIG representative or emailing uscorporateaccess@btig.com. This event provides an opportunity for investors to gain insights into Theravance Biopharma's current activities and future plans directly from the company's leadership.

Theravance Biopharma (NASDAQ: TBPH) has announced that it will release its second quarter 2024 financial results after market close on August 5, 2024. The company will also provide a business update during this report. Following the release, Theravance Biopharma will host a conference call and simultaneous webcast at 5:00 pm ET (2:00 pm PT/10:00 pm IST) on the same day.

Interested parties can pre-register for the telephone conference call or access the live webcast through the Investors section of Theravance Biopharma's website. A replay of the webcast will be available on the company's website for 30 days, until September 4, 2024.

Theravance Biopharma (NASDAQ: TBPH) reported first-quarter 2024 financial results, highlighting YUPELRI® sales of $55.2 million, an 18% increase year-over-year. Collaboration revenue with Viatris rose by 39% to $14.5 million. The company's Q1 ending cash balance was $100 million. R&D and SG&A expenses decreased to $9 million and $16.7 million, respectively. Theravance also reported a net loss of $11.7 million, down from $22.1 million in Q1 2023. The company is progressing with the CYPRESS study for ampreloxetine and has a key opinion leader event scheduled for May 23, 2024.

Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference and host in-person meetings with investors. The event will include a Fireside Chat on May 20 at 11:30 AM EDT. A webcast will be available on Theravance.com for 30 days.